DNLI - Denali Therapeutics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
DNLI price evolution
DNLI
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $74.68 | $60.57 | $127.11 | |
| Short term investments | $821.37 | $876.29 | $907.4 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $868.84 | $928.38 | $973.58 | $1064.14 |
| Long term investments | $450.99 | $490.72 | ||
| Property, plant & equipment | $113.22 | $72.61 | $72.17 | $71.64 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $574.18 | $607.52 | $89.78 | |
| Total investments | $1272.36 | $1367.02 | $907.4 | |
| Total assets | $1454.01 | $1502.57 | $1581.09 | $1153.92 |
| Current liabilities | ||||
| Accounts payable | $9.59 | $13.94 | $11.86 | $9.48 |
| Deferred revenue | $10.23 | $12.5 | ||
| Short long term debt | $7.77 | $7.51 | ||
| Total current liabilities | $87.09 | $74.53 | $82.58 | $77.98 |
| Long term debt | $5.63 | $40.98 | $43.03 | $44.98 |
| Total noncurrent liabilities | $40.98 | $43.03 | $44.98 | |
| Total debt | $48.75 | $50.55 | $44.98 | |
| Total liabilities | $135.52 | $115.51 | $125.62 | $122.96 |
| Shareholders' equity | ||||
| Retained earnings | -$1424.23 | -$1317.04 | -$1218.01 | -$1116.21 |
| Other shareholder equity | $5.53 | -$2.66 | -$1.3 | $0.64 |
| Total shareholder equity | $1387.05 | $1455.47 | $1030.95 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $127.11 | $218.04 | $293.48 | $507.14 |
| Short term investments | $907.4 | $1118.17 | $571.93 | $962.55 |
| Net receivables | $1.23 | $5.7 | ||
| Inventory | ||||
| Total current assets | $1064.14 | $1372.32 | $897.23 | $1495.65 |
| Long term investments | $425.45 | $32.7 | ||
| Property, plant & equipment | $71.64 | $74.52 | $69.61 | $73.46 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $89.78 | $87.92 | $506.93 | $108.63 |
| Total investments | $907.4 | $1118.17 | $997.38 | $995.25 |
| Total assets | $1153.92 | $1460.24 | $1404.16 | $1604.28 |
| Current liabilities | ||||
| Accounts payable | $9.48 | $2.79 | $4.78 | $1.07 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $77.98 | $363.92 | $378.25 | $71.7 |
| Long term debt | $44.98 | $53.03 | $58.55 | $64.17 |
| Total noncurrent liabilities | $44.98 | $53.89 | $63.63 | $382.05 |
| Total debt | $44.98 | $53.03 | $58.55 | $64.17 |
| Total liabilities | $122.96 | $417.81 | $441.87 | $453.75 |
| Shareholders' equity | ||||
| Retained earnings | -$1116.21 | -$970.99 | -$645 | -$354.42 |
| Other shareholder equity | $0.64 | -$6.89 | -$2.5 | -$0.24 |
| Total shareholder equity | $1030.95 | $1042.43 | $962.29 | $1150.53 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $91.4 | $107.02 | $107.8 | |
| Selling, general & administrative | $25.19 | $25.24 | $24.77 | |
| Total operating expenses | $123.19 | $116.59 | $117.72 | $132.57 |
| Operating income | -$116.59 | -$117.72 | -$132.57 | |
| Income from continuing operations | ||||
| EBIT | -$99.03 | -$101.8 | -$119.44 | |
| Income tax expense | $0.03 | |||
| Interest expense | $15.99 | |||
| Net income | ||||
| Net income | -$107.19 | -$99.03 | -$101.8 | -$119.47 |
| Income (for common shares) | -$99.03 | -$101.8 | -$119.47 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $330.53 | $108.46 | $48.66 | $335.66 |
| Cost of revenue | ||||
| Gross Profit | $330.53 | $108.46 | $48.66 | $335.66 |
| Operating activities | ||||
| Research & development | $423.88 | $358.73 | $265.35 | $212.62 |
| Selling, general & administrative | $103.35 | $90.47 | $79.06 | $60.33 |
| Total operating expenses | $527.23 | $449.21 | $344.41 | $272.94 |
| Operating income | -$196.7 | -$340.74 | -$295.75 | $62.72 |
| Income from continuing operations | ||||
| EBIT | -$145.19 | -$325.97 | -$291.16 | $71.96 |
| Income tax expense | $0.03 | $0.02 | -$0.57 | $0.82 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$145.22 | -$325.99 | -$290.58 | $71.14 |
| Income (for common shares) | -$145.22 | -$325.99 | -$290.58 | $71.14 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$99.03 | -$101.8 | -$119.47 | |
| Operating activities | ||||
| Depreciation | $1.94 | $2.16 | $2.18 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $25.1 | $27.84 | $25.99 | |
| Total cash flows from operations | -$91.22 | -$113.62 | -$98.66 | |
| Investing activities | ||||
| Capital expenditures | -$4.79 | -$2.15 | -$2.23 | |
| Investments | $103.36 | -$451.04 | $75.28 | |
| Total cash flows from investing | -$260.96 | $98.57 | -$453.19 | $73.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.76 | $500.27 | $4.71 | |
| Net borrowings | ||||
| Total cash flows from financing | $488.47 | $6.76 | $500.27 | $4.71 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$36.47 | $14.11 | -$66.53 | -$20.91 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$145.22 | -$325.99 | -$290.58 | $71.14 |
| Operating activities | ||||
| Depreciation | $16.73 | $10.38 | $8.59 | $8.53 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $108.1 | $99.85 | $85.25 | $50.35 |
| Total cash flows from operations | -$357.99 | -$244.72 | -$211.39 | $416.15 |
| Investing activities | ||||
| Capital expenditures | -$12.94 | -$17.83 | -$8.5 | -$3.1 |
| Investments | $262.25 | -$123.55 | -$13.13 | -$620.11 |
| Total cash flows from investing | $249.31 | -$141.39 | -$21.63 | -$623.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.82 | $310.67 | $19.35 | $634.75 |
| Net borrowings | ||||
| Total cash flows from financing | $17.82 | $310.67 | $19.35 | $634.75 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$90.86 | -$75.43 | -$213.67 | $427.69 |
News
Fundamentals
| Market cap | $2.34B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 143.84M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$427.49M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -5.48 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.97 |
|---|---|
| ROA | -30.04% |
| ROE | N/A |
| Debt/Equity | 0.12 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.98 |
| Quick ratio | N/A |